



## Immune Response and Vaccination Effectiveness against *Mycobacterium tuberculosis* Infection

Guest Editor:

**Prof. Dr. Pere-Joan Cardona**

Microbiology Department,  
Hospital Universitari Germans  
Trias i Pujol, Universitat  
Autònoma de Barcelona,  
Badalona, Catalonia, Spain

Deadline for manuscript  
submissions:

**closed (30 September 2023)**

### Message from the Guest Editor

Dear Colleagues,

Tuberculosis is still a major challenge for both humans and animals. BCG, the only vaccine that is currently available on the market, was designed 100 years ago. The lack of correlates of protection is one of the major hallmarks that hamper any quick and feasible development. There is a need for a better understanding of TB natural history in order to design reliable biomarkers. This should include not only ad hoc clinical trials, taking into account the One Health approach, but also information obtained from contact studies, including WGS from *M. tuberculosis* strains for better surveillance, to evaluate natural mechanisms of protection against active TB. On the other hand, new candidates both for human and animal protection have to fill the pipeline, so there is a need for new candidates, better experimental models for testing them, and the design of new tools, including in silico ones, to optimize clinical trials.

Prof. Dr. Pere-Joan Cardona  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)